Iron Sucrose

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Iron Sucrose
   1. Pharmacist Assessment Report
   2. Iron Sucrose: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Iron Sucrose: Known uses and market status in Australia

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Iron Sucrose, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use found is a relation recorded in the knowledge graph, not an approval.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
hyperphosphatemia (disease)

Australia Market Information

Licence	Product	Dosage form	Status
10229J	Venofer	Concentrate for solution for infusion 2.	Valid

Safety Considerations

• Drug Interactions: 42 interactions were identified in total. The only one rated Major is dimercaprol. Moderate interactions include:
  • Tetracycline antibiotics (doxycycline, minocycline, tetracycline) and chloramphenicol
  • Vitamin D analogues (cholecalciferol, calcifediol, ergocalciferol, dihydrotachysterol, doxercalciferol)
  • Bisphosphonates (alendronic acid, risedronic acid, ibandronate)
  • ACE inhibitors (benazepril, captopril, enalapril)
  • Thyroid hormones (levothyroxine, liothyronine, porcine thyroid)
  • Other iron products
• Potential concerns from the literature: Iron-induced oxidative stress and pancreatic beta cell toxicity (laboratory data only). Some intravenous iron products are also known to affect FGF23.

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---